(Q68055306)
Statements
Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma (English)
Melioli G
Margarino G
Scala M
Mereu P
Bertoglio S
Schenone G
Barbaresi M
Machí AM
Santi L